Literature DB >> 7039899

The treatment of hypertension by labetalol--a new alpha- and beta-adrenoreceptor blocking agent.

N Stern, A Teicher, T Rosenthal.   

Abstract

A new alpha- and beta-blocking agent, labetalol, was used to treat 50 hypertensive patients, 34 of them with refractory hypertension. A significant reduction in hypertension was achieved with relatively few adverse reactions. The combination of alpha and beta blockers in labetalol with their mutually opposing characteristics offers an interesting and promising approach to the control of hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039899     DOI: 10.1002/clc.4960050202

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Hypertension: a view from Detroit.

Authors:  R B Cubberley
Journal:  J Natl Med Assoc       Date:  1987-03       Impact factor: 1.798

Review 2.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 3.  Treatment Strategies for Paradoxical Hypertension Following Surgical Correction of Coarctation of the Aorta in Children.

Authors:  Peter P Roeleveld; Eline G Zwijsen
Journal:  World J Pediatr Congenit Heart Surg       Date:  2017-05

4.  Retrospective evaluation of labetalol as antihypertensive agent in dogs.

Authors:  Francesco Zublena; Chiara De Gennaro; Federico Corletto
Journal:  BMC Vet Res       Date:  2020-07-24       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.